Status of immunoPET: Wright and Lapi provide a brief review of the use of positron-emitting isotopes in tracking and imaging the localization of monoclonal antibodies and discuss the advancement of these technologies into clinical use.
Tumor hypoxia imaging in NSCLC: Bollineni and colleagues look at the potential added clinical value of the specific hypoxia tracer 18F-fluoroazomycin arabinoside over that of 18F-FDG in assessment of treatment in advanced-stage non–small cell lung cancer.
11C-tariquidar/11C-elacridar in humans: Bauer and colleagues investigate the suitability of these 2 radiolabeled P-glycoprotein and breast cancer resistance protein inhibitors for PET evaluation of P-glycoprotein density in the human brain.
Response quantification with SUV metrics: Vanderhoek and colleagues explore the impact of different standardized uptake value measures on quantification and classification of PET-based treatment response.
PET and survival in prostate cancer: Jadvar and colleagues correlate parameters derived from baseline 18F-FDG PET/CT with overall survival in men with castrate-resistant metastatic prostate cancer and discuss the implications for comparing effectiveness in treatment strategies.
Prediction of post-SIRT survival: Fendler and colleagues investigate the value of 18F-FDG PET/CT metabolic parameters in predicting survival after selective internal radiation therapy in patients with hepatic metastases from colorectal cancer.
18F-FLT PET and FOLFOX response: Hong and colleagues assess the use of 18F-FLT PET for early prediction of standard anatomic response and survival outcomes in patients with metastatic colorectal cancer receiving leucovorin, 5-fluorouracil, and oxaliplatin.
18F-FET PET in antiangiogenic treatment: Heinzel and colleagues evaluate the clinical utility and cost-effectiveness of the addition of 18F-FET PET to structural MR imaging in management of patients with recurrent high-grade glioma treated with bevacizumab and irinotecan.
PET in Merkel cell staging: Siva and colleagues determine the effect of 18F-FDG PET on prognostic stratification and management of Merkel cell carcinoma.
PET/CT and 131I therapy: Lee and colleagues look at the clinical benefit of 18F-FDG PET/CT performed concurrently with 131I therapy in patients with differentiated thyroid carcinoma and intermediate-to-high risk of recurrent disease.
MR, PET, and pediatric brain tumors: Zukotynski and colleagues describe a method for registering PET with MR permeability images to correlate 18F-FDG uptake, permeability, and cerebral blood volumes in pediatric brain tumors and compare these results with outcomes.
Imaging marrow involvement in DLBCL: Berthet and colleagues compare 18F-FDG PET/CT and bone marrow biopsy for detection of bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma.
SPECT and occupational radiation exposure: Duvall and colleagues assess the effects of changes in stress myocardial perfusion imaging protocols and high-efficiency SPECT camera technology in reducing occupational radiation exposure in a nuclear cardiology laboratory.
PET and MVO2: Wong and colleagues determine whether 11C-acetate PET can be used to quantify myocardial oxygen consumption in the hypertrophied right ventricle in patients with idiopathic pulmonary arterial hypertension.
GABA-A receptor imaging in cerebral palsy: Park and colleagues use 18F-fluoroflumazenil PET to investigate alterations in γ-aminobutyric acid-A receptor binding and functional and anatomic connectivity in the motor cortex in children with hemiplegic cerebral palsy.
18F-FMZ PET in epilepsy: Vivash and colleagues report on the results of a phase I/IIa study of the clinical use of 18F-FMZ PET for localization of epileptogenic zones in patients with drug-resistant temporal lobe epilepsy.
Olfactory tract and cortical metabolism: Cross and colleagues use 18F-FDG PET and diffusion tensor imaging to investigate the relationship of fiber tract integrity in the olfactory tract with cortical glucose metabolism in cognitively normal controls and individuals with mild cognitive impairment.
Kinetic modeling of 18F-JNJ-42259152: Van Laere and colleagues detail initial brain kinetic modeling of this novel phosphodiesterase-10A PET tracer and evaluate test–retest reproducibility in healthy volunteers.
99mTc-MAA distribution and 90Y-microspheres: Wondergem and colleagues determine the value of pretreatment 99mTc-macroaggregated albumin SPECT in predicting final activity distribution in 90Y-microsphere radioembolization for primary or metastatic liver malignancies.
11C-ITMM PET in humans: Toyohara and colleagues report on the safety, distribution, radiation dosimetry, and initial imaging of this agent for mapping metabotropic glutamate receptor type 1 in the brain.
α4β2-nAChR imaging: Wong and colleagues describe safety, test–retest reliability, and initial quantification in humans of 18F-AZAN, a novel radiotracer that binds to α4β2 nicotinic acetylcholine receptors.
Radioiodinated VAP-1 antibody: Autio and colleagues evaluate the performance of a fully human monoclonal anti–vascular adhesion protein-1 antibody in rabbits and discuss the clinical potential for imaging inflammation and for antiinflammatory therapy.
TSPO genotype and 11C-PBR28 SUV: Yoder and colleagues look at whether standardized uptake value measurements in brain 11C-PBR28 PET imaging can distinguish translocator protein 18 kDa affinity phenotypes in humans.
Skeletal imaging with SPECT/flat-panel CT: Lohrmann and colleagues assess the impact of high-resolution cone-beam CT with flat-panel detectors on interpretation of bone SPECT in diseases of the peripheral skeleton.
Pharmacokinetics of (EH)3 conjugates: Eder and colleagues provide biodistribution data on the ability of the (EH)3 purification tag to improve the pharmacokinetic properties of peptidic radiopharmaceuticals, with a focus on enhanced clearance from critical organs.
Imaging dopaminergic neurotransmission: Tatsch and Poepperl provide an educational update on nigrostriatal dopamine terminal imaging, with emphasis on SPECT performed with the presynaptic dopamine transporter ligand 123I-FP-CIT in patients with known or suspected parkinsonian syndrome.
18F-EF5 PET and antihypoxic therapy: Chitneni and colleagues evaluate the usefulness of 18F-EF5 PET imaging to monitor and predict tumor response to the hypoxia-activated prodrug SN30000 plus radiation treatment.
Cell-level activity quantification: Chouin and colleagues present a method for ex vivo activity quantification with an α-camera device, allowing activity measurement in tumor cells in very small biologic structures, with potential for small-scale dosimetry and targeted α-therapy.
PET imaging with 18F-FDM: Furumoto and colleagues describe a practical method for synthesis of this mannose derivative and stereoisomer of 18F-FDG and offer additional biologic evidence of its potential for tumor imaging.
PET and osteosarcoma: Campanile and colleagues characterize the different phenotypes of osteosarcoma by PET, comparing the uptake of 18F-FDG, 18F-FMISO, and 18F-fluoride in preclinical mouse models that reflect the heterogeneity of the human disease.
99mTc-PSMA inhibitors: Hillier and colleagues describe preclinical evaluation of 4 novel 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen with potential for molecular imaging of prostate cancer in humans.
11C-SA4503 uptake in pituitary tumors: Ramakrishnan and colleagues detail the kinetics of this PET tracer in tumor and brain in rats to explore its utility in detection of overexpression of σ-1 receptors in pituitary tumors.
ARBs and 18F-FDG uptake: Zhao and colleagues examine the effects of angiotensin II receptor blockers on 18F-FDG distribution and excretion in mice treated with telmisartan at different doses and discuss implications for clinical PET practice.
Pretargeted PET using click chemistry: Zeglis and colleagues report on the development of a methodology for pretargeted PET imaging with the potential for high-quality images and dramatically reduced nontarget radiation doses to patients.
Imaging of radiation injuries: Johnson and colleagues describe a technique using a γ-camera and 99mTc-tetracycline HCl to image temporal and spatial distribution of damage in susceptible tissues after high-dose radiation exposure.
Intratumoral distribution of 177Lu-mAbs: Örbom and colleagues investigate the distribution of 177Lu-DOTA-BR96 monoclonal antibodies targeting the Lewis Y antigen over 7 d using a syngeneic rat model of colon carcinoma.
18F-CPFPX model validation: Elmenhorst and colleagues report on the development and evaluation of practical pharmacokinetic models for quantification of the cerebral A1 adenosine receptor in high-resolution PET.
18F-labeled tracers for τ imaging: Okamura and colleagues detail the development of novel 18F-labeled arylquinoline derivatives, 18F-THK-5105 and 18F-THK-5117, for use in PET imaging of the microtubule-associated protein τ in neurofibrillary tangles in Alzheimer disease.
Ketamine and 5-HT2A receptor binding: Waelbers and colleagues use SPECT to investigate the brain kinetics of 123I-5-I-R91150, a 5-HT2A receptor antagonist, and the influence of ketamine on postsynaptic serotonin-2A receptor status in cats.
11C-PIB PET in transgenic mice: Snellman and colleagues assess the ability of 11C-Pittsburgh compound B PET to detect changes over time in β-amyloid deposition in the brains of 3 transgenic mouse models of Alzheimer disease.
SPECT imaging of VCAM-1: Dimastromatteo and colleagues explore the ability of twenty 99mTc-labeled major histocompatibility complex 1–derived peptide B2702p derivatives to facilitate imaging of vascular cell adhesion molecule 1 in an experimental model of atherosclerosis.
Systemic NIS gene therapy: Grünwald and colleagues use the sodium iodide symporter as a theranostic gene to investigate whether coating adenovirus with synthetic dendrimers could be useful in developing adenoviral vectors for combined oncolytic virotherapy and NIS-mediated radiotherapy.
Imaging GLP-1R in pancreas: Selvaraju and colleagues evaluate 68Ga-labeled exendin-4 for PET imaging and quantification of glucagonlike peptide 1 receptor–specific tissue uptake in vivo and discuss the implications for imaging native β-cells.
Phantom fluids for PET/MR: Ziegler and colleagues consider and assess different approaches to fluid selection for simultaneous PET/MR phantom imaging.
Adaptive template registration: Lundqvist and colleagues propose the use of an adaptive template registration method to overcome challenges in spatial normalization of PET amyloid imaging data.
FDA approval of diagnostic drugs: Gorovets and colleagues review specific approved diagnostic radiopharmaceuticals to illustrate the ways in which imaging performance is characterized in clinical studies and the clinical usefulness of imaging information included in drug labels.
Cardiac SPECT/CT and PET/CT 1.0: Dorbala and expert colleagues from the SNMMI, ASCC, and SCCT provide the full text of the latest collaborative guideline on cardiac SPECT/CT and PET/CT.
- © 2013 by the Society of Nuclear Medicine and Molecular Imaging, Inc.